Explore

Slice the corpus on any axis.

Filter by firm, year, function, metric or slide category — then see the result as a narrative arc, a treemap of slide types, or a catalog of slides.

clear
51,416 slides across 1229 decks match.
Treemap Arc Catalog
How will global employment evolve in the green growth era?
MorganStanley · 2023 · context
How will global employment evolve in the green growth era?
 What can governments and businesses do now to prepare for the green jobs transition?
MorganStanley · 2023 · problem_statement
What can governments and businesses do now to prepare for the green jobs transition?
 To respond to this demand and accelerate green jobs activation, we believe governments and policymakers need to shape strategies and create programs in the following four areas:
MorganStanley · 2023 · initiative_list
To respond to this demand and accelerate green jobs activation, we believe governments and policymakers need to shape strategies and create programs in the following four areas:
 The required shift to a green economy involves more than just creating and replacing jobs; it requires a fundamental restructuring of the labor market to ensure a sustainable and equitable transition.
MorganStanley · 2023 · quote_slide
The required shift to a green economy involves more than just creating and replacing jobs; it requires a fundamental restructuring of the labor market to ensure a sustainable and equitable transition.
 Can a universal carbon price be fair for everyone?
MorganStanley · 2023 · section_divider
Can a universal carbon price be fair for everyone?
 Most governments and climate experts agree we need carbon pricing to reach net zero. Delivering a just and fair transition is the hard part.
MorganStanley · 2023 · key_messages
Most governments and climate experts agree we need carbon pricing to reach net zero. Delivering a just and fair transition is the hard part.
 Why we need to increase carbon regulation now
MorganStanley · 2023 · problem_statement
Why we need to increase carbon regulation now
 Carbon taxes and trading schemes can lead to a more just transition, but current applications are suboptimal.
MorganStanley · 2023 · diagnosis
Carbon taxes and trading schemes can lead to a more just transition, but current applications are suboptimal.
US$95 billion — Revenue raised from carbon pricing
 How can we create a global carbon price framework?
MorganStanley · 2023 · problem_statement
How can we create a global carbon price framework?
 There are two main forms of CO2 accounting
MorganStanley · 2023 · framework_other
There are two main forms of CO2 accounting
 The case for pricing carbon as a commodity in the long term
MorganStanley · 2023 · diagnosis
The case for pricing carbon as a commodity in the long term
 What will a viable carbon price framework look like?
MorganStanley · 2023 · framework_other
What will a viable carbon price framework look like?
 Benefits of pricing carbon as a commodity in shaping the energy transition
MorganStanley · 2023 · scenario_analysis
Benefits of pricing carbon as a commodity in shaping the energy transition
68% — CO2 emissions
 How can governments shape carbon regulation to deliver value?
MorganStanley · 2023 · other
How can governments shape carbon regulation to deliver value?
 To meet our ambitious climate targets, we need to bring together global perspectives on carbon policy.
MorganStanley · 2023 · key_messages
To meet our ambitious climate targets, we need to bring together global perspectives on carbon policy.
 Financial Strength – Liquid and Growing¹
GoldmanSachs · 2023 · financial_analysis
Financial Strength – Liquid and Growing¹
$120.6 billion — Total Assets
 We Are a Highly Automated Electronic Broker
GoldmanSachs · 2023 · context
We Are a Highly Automated Electronic Broker
2.4mil — Client Accounts
 Earn Interest on Instantly Available Cash Balances
GoldmanSachs · 2023 · competitive_analysis
Earn Interest on Instantly Available Cash Balances
4.83% — USD Interest Rate
 Automation allows IBKR to be one of the lowest cost processors in the industry
GoldmanSachs · 2023 · impact_sizing
Automation allows IBKR to be one of the lowest cost processors in the industry
67% — Pretax Margin
 IBKR Growth Continues
GoldmanSachs · 2023 · industry_trends
IBKR Growth Continues
2,500 — Client Accounts
 IBKR Growth Continues
GoldmanSachs · 2023 · key_takeaways
IBKR Growth Continues
 IBKR’s Multiple Trading Platforms, Extensive Suite of Advanced Trading Tools, Algos and Order Types Continue to Earn Awards, Year After Year.
GoldmanSachs · 2023 · client_example
IBKR’s Multiple Trading Platforms, Extensive Suite of Advanced Trading Tools, Algos and Order Types Continue to Earn Awards, Year After Year.
 Pioneer in technology throughout the years
GoldmanSachs · 2023 · timeline
Pioneer in technology throughout the years
 The Leader in Sustained Release Drug Delivery for Retinal Disease
GoldmanSachs · 2025 · key_messages
The Leader in Sustained Release Drug Delivery for Retinal Disease
$318M — Cash runway
 Pipeline Leveraging Durasert E™ Drug Delivery Technology Pursuing Large Market Opportunities
GoldmanSachs · 2025 · roadmap
Pipeline Leveraging Durasert E™ Drug Delivery Technology Pursuing Large Market Opportunities
 There is a Significant Need for More Durable Therapies in Wet AMD
GoldmanSachs · 2025 · problem_statement
There is a Significant Need for More Durable Therapies in Wet AMD
80% — treatment compliance
 Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments
GoldmanSachs · 2025 · market_sizing
Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments
$3.0B — Global branded market
 DURAVYU Demonstrated Positive Efficacy Outcomes and Excellent Safety Profile Across Multiple Indications
GoldmanSachs · 2025 · case_study
DURAVYU Demonstrated Positive Efficacy Outcomes and Excellent Safety Profile Across Multiple Indications
190 — Patient count
 DURAVYU De-Risked Clinical Approach in Wet AMD
GoldmanSachs · 2025 · problem_statement
DURAVYU De-Risked Clinical Approach in Wet AMD
 Ongoing DURAVYU Phase 3 Trials in Wet AMD Supported by Phase 2 DAVIO 2 Results - All Primary and Secondary Endpoints Met
GoldmanSachs · 2025 · case_study
Ongoing DURAVYU Phase 3 Trials in Wet AMD Supported by Phase 2 DAVIO 2 Results - All Primary and Secondary Endpoints Met
 Phase 3 Pivotal Trials - Designed to Evaluate Non-Inferiority of DURAVYU vs Aflibercept Control
GoldmanSachs · 2025 · process_diagram
Phase 3 Pivotal Trials - Designed to Evaluate Non-Inferiority of DURAVYU vs Aflibercept Control
 Phase 3 Clinical Trials for DURAVYU in wet AMD Seeing Exceptional Enrollment Rates Driven by Significant Investigator and Patient Enthusiasm
GoldmanSachs · 2025 · timeline
Phase 3 Clinical Trials for DURAVYU in wet AMD Seeing Exceptional Enrollment Rates Driven by Significant Investigator and Patient Enthusiasm
 DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies
GoldmanSachs · 2025 · competitive_analysis
DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies
6-month — Dosing frequency
 The VERONA Phase 2 Clinical Trial is the First Trial DURAVYU was Evaluated in Patients with Active Disease
GoldmanSachs · 2025 · process_diagram
The VERONA Phase 2 Clinical Trial is the First Trial DURAVYU was Evaluated in Patients with Active Disease
 VERONA: Phase 2 Clinical Trial Met Primary and Key Secondary Endpoints
GoldmanSachs · 2025 · case_study
VERONA: Phase 2 Clinical Trial Met Primary and Key Secondary Endpoints
+7.1 — BCVA improvement
 Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA; Supports Noninferiority in Pivotal Trial
GoldmanSachs · 2025 · case_study
Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA; Supports Noninferiority in Pivotal Trial
+7.1 — Mean Change in BCVA
 Excluding a Single Outlier Patient, DURAVYU 2.7mg Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control
GoldmanSachs · 2025 · financial_analysis
Excluding a Single Outlier Patient, DURAVYU 2.7mg Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control
+10.1 — Change in ETRDS letters
 DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying than Aflibercept Control
GoldmanSachs · 2025 · case_study
DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying than Aflibercept Control
74% — Mean change in CST
 Sub-Group of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual and Anatomical Outcomes
GoldmanSachs · 2025 · case_study
Sub-Group of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual and Anatomical Outcomes
+10.3 — Mean Change in BCVA
 VERONA Clinical Trial Case Study 1 - Rapid Drying with Improved Vision After Single DURAVYU 2.7mg Treatment and No Supplementation
GoldmanSachs · 2025 · case_study
VERONA Clinical Trial Case Study 1 - Rapid Drying with Improved Vision After Single DURAVYU 2.7mg Treatment and No Supplementation
67 — BCVA
 VERONA Clinical Trial Case Study 2 - Continued Drying at Week 24 with Improved VA After Single DURAVYU 2.7mg Treatment and No Supplementation
GoldmanSachs · 2025 · case_study
VERONA Clinical Trial Case Study 2 - Continued Drying at Week 24 with Improved VA After Single DURAVYU 2.7mg Treatment and No Supplementation
80 — BCVA
 State-Of-The-Art cGMP Manufacturing Facility to Support DURAVYU through Phase 3 and Global Commercial Production
GoldmanSachs · 2025 · case_study
State-Of-The-Art cGMP Manufacturing Facility to Support DURAVYU through Phase 3 and Global Commercial Production
 On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones
GoldmanSachs · 2025 · timeline
On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones
 We Love SaaS Globally
Accel · other
We Love SaaS Globally
135 — SaaS investments
 $2.5 Billion Invested in Cloud Companies
Accel · financial_analysis
$2.5 Billion Invested in Cloud Companies
$2.5bn — Investment Volume
 SaaS continues to eat Software
Accel · industry_trends
SaaS continues to eat Software
$125B — Revenue
 SMB is getting real
Accel · market_landscape
SMB is getting real
10,100 — USD Millions
 Cloud Index grew 350% since 2011
Accel · market_landscape
Cloud Index grew 350% since 2011
350% — Cumulative Growth
Next page →